Citius Pharmaceuticals Inc (NASDAQ:CTXR) has a beta value of 1.11 and has seen 97509.0 shares traded in the last trading session. The company, currently valued at $23.11M, closed the last trade at $2.69 per share which meant it lost -$0.01 on the day or -0.37% during that session. The CTXR stock price is -894.42% off its 52-week high price of $26.75 and 9.29% above the 52-week low of $2.44. If we look at the company’s 10-day average daily trading volume, we find that it stood at 72710.0 shares traded. The 3-month trading volume is 288.98K shares.
The consensus among analysts is that Citius Pharmaceuticals Inc (CTXR) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.25.
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Sporting -0.37% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CTXR stock price touched $2.69 or saw a rise of 5.61%. Year-to-date, Citius Pharmaceuticals Inc shares have moved -32.75%, while the 5-day performance has seen it change 0.75%. Over the past 30 days, the shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) have changed -20.88%. Short interest in the company has seen 0.51 million shares shorted with days to cover at 3.17.
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
The company’s shares have lost -81.77% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
2 analysts offering their estimates for the company have set an average revenue estimate of 2.67M for the current quarter. 2 have an estimated revenue figure of 4M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.90% over the past 5 years.
CTXR Dividends
Citius Pharmaceuticals Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Insiders own 5.74% of the company shares, while shares held by institutions stand at 8.09% with a share float percentage of 8.58%. Investors are also buoyed by the number of investors in a company, with Citius Pharmaceuticals Inc having a total of 34.0 institutions that hold shares in the company. The top two institutional holders are ARMISTICE CAPITAL, LLC with over 10.16 million shares worth more than $5.93 million. As of 2024-06-30, ARMISTICE CAPITAL, LLC held 6.3845% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.33 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.69 million and represent 3.9776% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024 , the former fund manager holds about 1.93% shares in the company for having 165.58 shares of worth $0.45 million while later fund manager owns 78.32 shares of worth $0.21 million as of Sep 30, 2024 , which makes it owner of about 0.91% of company’s outstanding stock.
